Reuters logo
BRIEF-Glaxosmithkline says Phase III PETIT2 study meets primary endpoint
June 13, 2014 / 6:50 AM / 3 years ago

BRIEF-Glaxosmithkline says Phase III PETIT2 study meets primary endpoint

June 13 (Reuters) - Glaxosmithkline Plc

* GSK announces results of phase iii petit2 study of eltrombopag (promacta /revolade) in paediatric patients with chronic immune thrombocytopenia

* Efficacy results for petit2 were consistent across age cohorts

* Eltrombopag-marketed as promacta in u.s. And as revolade in europe and other countries across world-met its primary endpoint

* Study achievid a statistically significant improvement in platelet counts with almost 40 percent of patients treated with eltrombopag attaining a consistent platelet response for 6 of 8 weeks compared to placebo (39.7 percent versus. 3.4 percent, respectively, p<0.001).

* Most common adverse events (aes) occurring most frequently in eltrombopag arm included nasopharyngitis, rhinitis, cough and respiratory tract infection

* Serious aes were reported in 8 percent of eltrombopag-treated patients versus. 14 percent in placebo arm. Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below